Malignant astrocytic glioma: genetics, biology, and paths to treatment
Top Cited Papers
Open Access
- 1 November 2007
- journal article
- review article
- Published by Cold Spring Harbor Laboratory in Genes & Development
- Vol. 21 (21) , 2683-2710
- https://doi.org/10.1101/gad.1596707
Abstract
Malignant astrocytic gliomas such as glioblastoma are the most common and lethal intracranial tumors. These cancers exhibit a relentless malignant progression characterized by widespread invasion throughout the brain, resistance to traditional and newer targeted therapeutic approaches, destruction of normal brain tissue, and certain death. The recent confluence of advances in stem cell biology, cell signaling, genome and computational science and genetic model systems have revolutionized our understanding of the mechanisms underlying the genetics, biology and clinical behavior of glioblastoma. This progress is fueling new opportunities for understanding the fundamental basis for development of this devastating disease and also novel therapies that, for the first time, portend meaningful clinical responses.Keywords
This publication has 258 references indexed in Scilit:
- FoxOs Are Lineage-Restricted Redundant Tumor Suppressors and Regulate Endothelial Cell HomeostasisCell, 2007
- Ubiquitination Regulates PTEN Nuclear Import and Tumor SuppressionCell, 2007
- AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma PatientsCancer Cell, 2007
- A negative feedback signaling network underlies oncogene-induced senescenceCancer Cell, 2006
- Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycinCancer Cell, 2006
- A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in gliomaCancer Cell, 2006
- RETRACTED: Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesisCancer Cell, 2003
- Phosphatidylinositol-3-OH kinase direct target of RasNature, 1994
- A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4Nature, 1993
- Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53Nature, 1993